CompletedNot Applicable

Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate

Denmark28 participantsStarted 2020-09-19

Plain-language summary

The main objective of this study is to assess if analysis of exhaled breath condensate (EBC) can provide useful prognostic markers for admission to the intensive care unit (ICU) due to acute respiratory insufficiency among patients with Coronavirus disease 2019 (COVID-19). Additionally, to give a characterization of the lung damage caused by COVID-19 by analysis of daily blood samples. The hypothesis is that the protein content of the EBC from COVID-19 patients who require admission to the ICU differs from the EBC from COVID-19 patients with uncomplicated hospitalization, potentially providing diagnostic markers of COVID-19 related pulmonary damage.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years and admitted at Aalborg Hospital with confirmed COVID-19 * Need for hospitalization due to COVID-19 symptoms. * Able to provide informed consent Exclusion Criteria: • Need for vasopressor therapy, mechanical ventilation, extracorporal circulation, or dialysis at admission

What they're measuring

Prediction of admission to ICU in hospitalized COVID-19 patients

Timeframe: 1 year

Trial details

NCT IDNCT04598620

SponsorInger Lise Gade

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-10-01

View on ClinicalTrials.gov More Covid19 trials